Despite significant progress in the past 30 years, HIV continues to be a major global health issue, having claimed more than 39 million lives to date. According to UNAIDS, in 2013, there were 35 million people living with HIV and 1.5 million who died of HIV-related illnesses worldwide. In particular, women and young girls bear the brunt of HIV globally, accounting for 22 percent of new infections. From the ages of 15 to 24, young women face HIV infection rates twice as high as young men.
Reimagining Global Health (a recently published report by the Innovation Countdown 2030 initiative) features 30 high-impact innovations selected by independent experts for their promise to save lives. The report identifies three HIV-specific innovations that could help turn the tide of the epidemic—broadly neutralizing antibodies (bNAbs) in HIV vaccines, oral pre-exposure prophylaxis (PrEP) for HIV prevention, and long-acting injectable antiretroviral (ARV) drug therapy.
We are providing an open forum on this blog for leaders from the HIV/AIDS community to offer their opinions on the ways these and other technologies could advance HIV prevention and treatment and potentially change the trajectory of the AIDS epidemic worldwide. Contributions will be published over the next two weeks as a three-part series entitled “Innovating against HIV.” In our first installment below, AVAC, the International AIDS Vaccine Initiative (IAVI), and CAMI Health kick off the discussions.
Views expressed are those of the contributors and may not be shared by PATH.